Clinical Trials Browser

OTHER × Prostatic Neoplasms × bicalutamide × Clear all

NCT07593079 2026-05-18

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT07455903 2026-05-13

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Phase 2 Recruiting

Prostatic Neoplasms

NCT04513717 2026-05-04

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02346253 2026-04-13

High-Dose Brachytherapy in Treating Patients With Prostate Cancer

Phase NA Active not recruiting

Prostatic Neoplasms

NCT05700903 2026-03-02

ARCH

Phase 4 Completed

Hypertension, Kidney Diseases, Prostatic Neoplasms, Primary Dysautonomias

NCT06650579 2026-02-24

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT01786265 2026-02-20

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07393867 2026-02-06

ARPEGGIO

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT04734730 2026-01-28

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

Phase 2 Recruiting

Prostatic Neoplasms

NCT03809000 2025-12-30

STEEL

Phase 2 Active not recruiting

188 enrolled 25 charts

Prostatic Neoplasms

NCT03009981 2025-12-18

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT04025372 2025-12-15

INTREPId (INTermediate Risk Erection PreservatIon Trial)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06528210 2025-09-23

Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer

Phase 2 Withdrawn

Prostatic Neoplasms

NCT01342367 2025-06-10

Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer

Phase NA Active not recruiting

74 enrolled 12 charts

Prostatic Neoplasms

NCT00328614 2025-05-16

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Phase 1 Completed

32 enrolled 12 charts

Prostatic Neoplasms

NCT01420250 2025-05-15

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00223145 2025-01-27

PCS III

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT02366494 2024-11-25

Micro RNAs to Predict Response to Androgen Deprivation Therapy

Prostatic Neoplasms

NCT03141671 2024-05-14

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT03358563 2024-05-03

Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00099086 2024-01-31

Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00482807 2023-11-24

Radiation Therapy, Docetaxel, and Hormone Therapy in High-Risk Locally Advanced Metastasized Prostate Cancer

Phase 1 Completed

Prostatic Neoplasms

NCT00541047 2023-11-13

RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery

Phase 3 Completed

GenitourinaryOther

Prostatic Neoplasms, Sexual Dysfunction, Physiological

NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

Phase 2 Completed

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

NCT02058706 2023-05-10

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 2 Completed

71 enrolled 18 charts

Prostatic Neoplasms

NCT05019846 2023-04-18

SPA

Phase 3 Recruiting

Prostatic Neoplasms

NCT03043807 2023-02-16

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Phase 2 Completed

26 enrolled 8 charts

Prostatic Neoplasms

NCT00055731 2023-01-18

Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse

Phase 3 Completed

Prostatic Neoplasms

NCT02064036 2022-10-18

CCRO025

Phase 1 Completed

Prostatic Neoplasms

NCT02716974 2022-08-04

oligo-mets

Phase 2 Completed

26 enrolled 8 charts

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Prostatic Neoplasms

NCT02614859 2022-03-29

BIMET-1

Phase 2 Completed

29 enrolled 10 charts

Prostatic Neoplasms

NCT04248621 2021-07-29

Androgen Deprivation Therapy on Bone Mineral Density Change in Prostate Cancer Patients

Phase 4 Unknown

Prostatic Neoplasms

NCT03541928 2021-04-06

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

Phase 2 Unknown

Prostatic Neoplasms

NCT02059213 2020-09-16

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Phase 2 Completed

72 enrolled 15 charts

Prostatic Neoplasms

NCT02742675 2020-07-07

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Phase 2 Unknown

Prostatic Neoplasms

NCT00003645 2020-04-28

Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence

Phase 3 Terminated

64 enrolled 12 charts

Prostatic Neoplasms

NCT00702923 2019-11-21

CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer

Phase 1 Terminated

12 enrolled 9 charts

Prostatic Neoplasms

NCT00669162 2019-07-24

Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer

Phase 1/2 Completed

27 enrolled 7 charts

Prostatic Neoplasms

NCT03996993 2019-06-25

Defining Recurrent Disease With Axumin™

Prostatic Neoplasms

NCT00924807 2018-12-11

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

Phase 1/2 Terminated

4 enrolled 4 charts

Prostatic Neoplasms

NCT00002855 2018-10-31

Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT00298155 2018-08-09

TAPS

Phase 2 Completed

35 enrolled 6 charts

Neoplasms, Prostatic Neoplasms

NCT00283803 2018-08-07

Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer

Phase 2 Completed

32 enrolled 9 charts

Prostatic Neoplasms

NCT00165399 2018-06-25

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Phase 2 Completed

Prostatic Neoplasms

NCT00878436 2018-02-07

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Phase 1/2 Completed

52 enrolled 8 charts

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT00814788 2018-01-10

UCDCC#215

Phase 2 Completed

24 enrolled 9 charts

Prostatic Neoplasms

NCT00630344 2017-12-08

RAD001 and Bicalutamide for Androgen Independent Prostate Cancer

Phase 2 Completed

36 enrolled 10 charts

Prostatic Neoplasms

NCT02605226 2017-06-12

CRYO-PCA-III

Phase NA Unknown

Prostatic Neoplasms